| Unique ID issued by UMIN | UMIN000008017 |
|---|---|
| Receipt number | R000009431 |
| Scientific Title | Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019> |
| Date of disclosure of the study information | 2012/05/23 |
| Last modified on | 2020/11/30 12:33:30 |
Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
| Japan |
follicular lymphoma
| Hematology and clinical oncology |
Malignancy
YES
To investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma[FL]
Safety,Efficacy
Exploratory
Phase II
Progression free survival at 2 years[2y PFS]
Best Response Rate, Complete Response Rate, Overall Response Rate, Overall survival, Progression Free Survival, Bcl-2 negative conversion rate, Minimal Residual Disease, Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
| Medicine |
Rituximab combination chemotherapy 1course/3W [Maximum 6-8 course]
Rituximab monotherapy 1course/8W[until 2 years]
Rituximab 375 mg/m2 div day0 or day1
| 18 | years-old | <= |
| 75 | years-old | > |
Male and Female
1)Follicular lymphoma[FL]
[exclude patients with Histologic transformation]
2)grade 1, 2, 3a
3)no previous chemotherapy
4)CD20 positive
5)Age:18 to 74
6)Performance Status:0 to 2
7)having musurable lesion
8-1)WBC:3,000/mm3 or more
Neutrophil:1,200/mm3 or more
Platlets:7.5x10^4/mm3 or more
8-2)AST[GOT]/ALT[GPT]:5xnormal upper
limit or less
T-bil:2.0mg/dL or less
8-3)Creatinine:1.5mg/dL or less
9)Written informed consen
1)active double cancer
2)severe infection or severe complication
3)having prior drug allergy
4)prior treated heart failure or renal failure
5)Cirrhosis of the liver
6)HBs-Ag positive
7)Disorder of electrocardiogram, Disorder of heart fanction, severe heart disease
8)pregnant/lactating woman
9)psychosis
10)given systemic steroid
11)Physician's decision of inappropriateness
24
| 1st name | Eijiro |
| Middle name | |
| Last name | Omoto |
Yamagata Prefectural Central Hospital
Department of Hematology
990-2292
1800 Aoyagi, Yamagata city, Yamagata, 990-2292, JAPAN
023-685-2626
ej-omoto@vega.ocn.ne.jp
| 1st name | Eijiro |
| Middle name | |
| Last name | Omoto |
Yamagata Prefectural Central Hospital
Department of Hematology
990-2292
1800 Aoyagi, Yamagata city, Yamagata, 990-2292, JAPAN
023-685-2626
ej-omoto@vega.ocn.ne.jp
TOHOKU HEMATOLOGY FORUM
Tohoku Hematology Expert Meeting (THEMe)
Self funding
TOHOKU HEMATOLOGY FORUM
IRB of Yamagata Prefectural Central Hospital
1800 Aoyagi, Yamagata City, Yamagata
0236852626
eomoto@ypch.gr.jp
NO
| 2012 | Year | 05 | Month | 23 | Day |
Unpublished
24
No longer recruiting
| 2012 | Year | 04 | Month | 27 | Day |
| 2012 | Year | 05 | Month | 16 | Day |
| 2012 | Year | 06 | Month | 01 | Day |
| 2022 | Year | 05 | Month | 01 | Day |
| 2012 | Year | 05 | Month | 23 | Day |
| 2020 | Year | 11 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009431